Ideaya Biosciences Inc $IDYA

Recent News (5)

• IDEAYA Biosciences Announces London Investor R&D Day and Participation in Upcoming September 2026 Investor Conferences PR Newswire · 01 Sep 2026 SOUTH SAN FRANCISCO, Calif., Sept. 1, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therape…
• IDEAYA Biosciences Announces Successful FDA Type C Meeting for IDE849, DLL3 TOP1 ADC, on Phase 3 Registrational Trial Design for Potential Accelerated and Full Approval in Extensive Stage Small Cell Lung Cancer PR Newswire · 31 Aug 2026 Based on FDA Type C meeting, targeting to initiate a randomized Phase 3 registrational trial for IDE849 monotherapy by year-end 2026 in ES-SCLC, with ORR by BICR as the primary endpoint for potential …
• IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PR Newswire · 28 Aug 2026 SOUTH SAN FRANCISCO, Calif., Aug. 28, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therape…
• IDEAYA Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update PR Newswire · 04 Aug 2026 Registrational OptimUM-02 trial of the darovasertib combination in metastatic uveal melanoma (mUM) met its primary endpoint; new drug application (NDA) filing is underway under the real-time oncology …
• IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PR Newswire · 31 Jul 2026 SOUTH SAN FRANCISCO, Calif., July 31, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therape…